Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00553969 · ClinicalTrials.gov registry record · Phase 1

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

A Phase 1 study, sponsored by University of Minnesota.

Completed
Registry status
Phase 1
Development phase
101
Enrollment target

NCT00553969: Completed Phase 1 study, sponsored by University of Minnesota.

NCT00553969 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 101 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00553969, a Phase 1 study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 1
Development phase
101 participants
Enrollment target

Study Summary

This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study period. Patients to be randomized will have pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least one additional cardiovascular risk factor.

Primary Outcome

Rasmussen Disease Score (RDS) Change From Baseline to 9 Months A score of six or higher on these tests means the patient likely has plaque build-up in the arteries, or atherosclerosis, while a score of three to five suggests that such a problem may be developing. A score of two or less signals a patient is fine but should return in the future for another test. The method detects disease at the earliest moment, before the traditionally used calcium score would show any signs of trouble.

Interventions

  • DRUG lisinopril
  • DRUG carvedilol phosphate
  • DRUG carvedilol phosphate and lisinopril
  • DRUG placebo and placebo

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2007-11
Est. Completion 2010-12
Phase Phase 1
University of Minnesota

966 total trials

What the finished NCT00553969 record still lists

NCT00553969 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% higher).

The record links to 0 conditions, and to 4 interventions - of which lisinopril is the first listed.

NCT00553969 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00553969 about?

NCT00553969 is a clinical study titled "Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease". This study will examine the individual and combined effects of Coreg CR and lisinopril, on cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo controlled comparison over a 9-month study period. Patients to be randomized will have pre-hypertensive blood pressures ...

What is the current status of trial NCT00553969?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2007-11. Estimated completion is 2010-12.

What interventions are being tested in trial NCT00553969?

The interventions under investigation include: lisinopril (DRUG), carvedilol phosphate (DRUG), carvedilol phosphate and lisinopril (DRUG), placebo and placebo (DRUG).

Who is sponsoring clinical trial NCT00553969?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00553969's enrollment target sits among peer trials

101 546th of 2000 higher than 1,455 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00553969, the US trial registry maintained by the National Library of Medicine. NCT00553969 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.